ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GSK Gsk Plc

1,705.00
-0.20 (-0.01%)
Last Updated: 13:04:27
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.20 -0.01% 1,705.00 1,705.20 1,705.60 1,709.60 1,699.40 1,701.60 1,078,802 13:04:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.25 70.24B

Genmab: 2Q Sales of Leukemia Drug Arzerra Totaled GBP12.8 Million

23/07/2014 12:50pm

Dow Jones News


Gsk (LSE:GSK)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Gsk Charts.
   By Dominic Chopping 
 

Danish pharmaceutical company Genmab A/S (GEN.KO) said Wednesday that net sales of leukemia drug Arzerra (ofatumumab) during the second quarter of 2014 were GBP12.8 million.

This figure consists of net sales in the US of GBP6.9 million and in the rest of the world of GBP5.9 million.

Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK23 million.

The second quarter net sales did not include sales related to the supply of ofatumumab for clinical trials run by other parties.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock